Introducing our latest innovation in diagnostic testing - the Bead Immunoassay. This cutting-edge technology offers a highly sensitive and accurate method for detecting a wide range of analytes in biological samples. The Bead Immunoassay utilizes color-coded microspheres coated with specific antibodies to target antigens of interest, allowing for the simultaneous measurement of multiple analytes in a single sample. This multiplexing capability makes the Bead Immunoassay ideal for high-throughput screening and profiling of biomarkers in various clinical and research applications. Our Bead Immunoassay platform is designed to deliver reliable and reproducible results, even at low analyte concentrations, making it an invaluable tool for early disease detection and monitoring. With its customizable panel configurations and flexible assay formats, our Bead Immunoassay system offers the versatility to meet the specific needs of different laboratories and research settings. Furthermore, the user-friendly software interface and automated workflow streamline the testing process, saving time and reducing the potential for human error. Whether you are conducting biomarker discovery, drug development, or clinical diagnostics, our Bead Immunoassay technology provides a powerful and efficient solution for multiplexed analyte detection. Join the forefront of immunoassay technology with our Bead Immunoassay platform and unlock new possibilities in biomedical research and diagnostic testing.

Beijing, China - In a groundbreaking development, researchers at Beijing Beier Bioengineering Co., Ltd. have announced a major breakthrough in the fight against Treponema Pallidum, the bacterium that

Beijing Beier Bioengineering Co., Ltd., a high-tech enterprise in China specializing in the development and production of in vitro diagnostic reagents, has recently introduced a new Rtk Antigen Self T